Importantly, this aspect may have deep implications in terms of suboptimality of male BC management since this entity is substantially enriched for HR+/HER2-cases [7], thus making endocrine-based therapy the main backbone of treatment also for men, both in the early and advanced setting. This evidence concerns the gene ERBB2 and breast cancer.